Clinical Locations
Huntsman Cancer Institute - Cancer Research North
Board Certification
|
Educational Commission for Foreign Medical Graduates
American Board of Internal Medicine (Sub: Medical Oncology)
|
Patient Rating
The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.
The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient Comments
Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.
I would tell anyone that has CLL to try to get Dr. Halwani as their doctor. He cares and shows it plus he just has a wonderful personality to make a person feel good and safe with him. Any questions, he will answer do you can understand. Can't say anything more except he is a wonderful, caring doctor and person.
Dr. Halwani is very caring and so wonderful to work with, I know he cares about me and helps me understand and get the care I need.
I am so fortunate to have Dr. Halwani as my doctor. He is so smart and knowledgeable. He takes his time during our appointments and explains all options throughly and clearly. I trust him implicitly!
Awesome Dr and very thoughtful and kind.
I will do that.
Dr. Halwani is knowledgeable, kind, professional and an expert in his field. He's been my caregiver for 3 years. It gives me tremendous peace knowing he is my physician.
.
Caring and Great Dr.
Dr Halwani is very knowledgeable and shows great care and willing to spend time with the patient to help me understand things.
Dr. Halwani is an excellent doctor. He is always welcoming, interested, and easy to talk with. IÕve been seeing him every 6 months and having a blood draw for several years. IÕm in remission, but he wants to insure I donÕt relapse. a relapse.
Dr. Halwani is amazing. He makes a person feel comfortable and important. He listens and explains. Very caring and lighthearted
Dr. Halwani is an excellent person. He explains everything very well. [TRANSLATED]
Dr. Halwani is very personable and caring. He makes time to listen and talk with a person.
Highly recommend Dr. Halwani who is experienced, takes his profession seriously, yet has a good sense of humor.
He is always so friendly and positive. Always makes me feel relaxed and important.
Dr. Halwani is the best doctor I have ever had! He is so kind and caring, I'm grateful he is my doctor.
Dr. Halwani has been the most excellent Doctor I would have no trouble recommending him to anyone
Dr. Halwani and his superior team is the gold standard of care. Thorough, insightful and compassionate. I am so grateful my health is in his care!
Dr. Halwani is wonderful. I'm grateful to ge in his care.
Dr Halwani is very caring and always makes sure I understand everything.
Dr. Halwani is a thoughtful, experienced and caring physician. My husband has been seeing him regularly from his initial non-Hopkins Lymphoma in 2011. Doctor listens carefully and engages one's confidence immediately. We highly recommend Dr. Halwani.
The best doctor I have ever had.
Doctor Halwani has been with me for 12 years He is the best.That is why I`m still alive.
Dr Halwani is a wonderful anthologist and great at answering all of my questions as well as explaining all the proceedures and what all of the drugs were used for and their effects on me I would recommend him to anyone going through cancer treatment
Dr. Halwani is a wonderful, caring physician.
It's my first experience with Dr Halwani or any oncologist but he has given me a great feeling of confidence in being in his care and providing me with the best treatments for this next step in my life
I'm very happy Dr. Halwani is my doctor. He makes me feel so at ease. I trust him completely in making the right decisions about me.
A Wonderful doctor
Caring, makes an effort to communicate both in the building and via email. Very appreciative with Dr. H.
Great bedside manner. Knowledgeable explains issues in a way I can understand..
For lymphoma, Dr. Halwani is an expert and a very caring physician. I'm so thankful I was directed to him.
Dr. Halwani is very personable. He makes me feel very comfortable by listening and answering all questions.
I like having him very much for my doctor. He's always so positive and support. He has a very happy light personality.
I have been so blessed to have Dr. Halwani to guide me to health in this journey. He has been amazing. At my last visit, I spoke with him about cancer concerns for my son. He guided me to the right doctor . . . the right new patient scheduling person . . . and explained why this was the place for his best care. My relief was huge! I am grateful always to have his expertise and care.
Great bedside manner. Easy to discuss things with. Very informative. I feel very comfortable and at ease during our visits.
Dr Halwani is always a pleasure to work with and does a good job of reviewing and explaining the results of my blood tests. I appreciate the time he spends reviewing my health history.
Dr Halawani is very kind and very thorough
He is the best
Dr. Halwani always greets with a happy personality and a very caring attitude. He listens very carefully and explains in a manner I understand
Dr. Halwani is a very caring doctor who has handled my CLL with utmost professionalism
Very good. Explains everything so that my family and I know whats happening and in a way we understand.
A compassionate and energetic oncologist, a great communicator, and a leader in lymphoma treatment and research. I am very grateful I was referred to Dr. Halwani. His Fellow who works with him is excellent as well and getting very good training.
I really liked Dr Halwani. Hes knowledgeable and caring and was always ready to move on the the next step in my treatment when it was needed.
Doctor was rude and lecturing us about why were there when we were simply doing what our primary physician told us to to follow-up. The doctor lectured us for quite a while repeating that in all essence we were wasting his time. To clarify this was the doctor and NOT the nurse practitioner who came in first. She was phenomenal. He very simply could have told us that he had no cancer concerns at this time and that there is no need to follow up with the Huntsman unless something changes. Was a terrible experience with him.
Dr. Halwani is great he's never in a rush, he has very good communication skills with those in his care.
Extra care was given when an unexpected lab value created a tense situation
Dr Hulwani is patient and caring and never acts rushed or put out by my many questions. He is truly concerned about me and my health. I have felt safe in his hands since day one. He is gentle and kind, and that is much appreciated when you're scared and sick.
Very clear at explaining my particular situation and the current research findings and data related to positive outcome
Dr. Halwani is an exceptional Doctor. We trust his expertise, he explains the different results in a manner we can understand, tells us the different options available in dealing with the different issues. Truly thankful for being under his medical care.
The doctor was very attentive. He listened and answered all my questions fully and in a way I could understand.
Dr. Halwani was outstanding in regards to providing information and listening to my concerns. The atmosphere was relaxed and friendly while very professional.
I was glad that he listened to my concerns and gave me some help in areas where I felt previous providers didn't show concern.
very informative
very helpful explanations of possibilities
Really impressed with the staff and Jess and DR Hawanii
It was a good experience. It would be helpful if notes about the visit were attached to MyChart afterwards.
Dr Hulwani is easy to talk to, never seems rushed and explains things in a way I can understand. He is always upbeat and kind.
good
Dr. Halwani showed genuine care and concern and I know that I am a priority when I'm there.
good
Board Certification and Academic Information
| Academic Departments |
Internal Medicine
-Associate Professor (Clinical) |
|---|---|
| Academic Divisions |
Hematology & Hematologic Malignancies
|
| Board Certification |
Educational Commission for Foreign Medical Graduates
American Board of Internal Medicine (Sub: Medical Oncology)
|
Education history
| Undergraduate | Biology with High Distinction - American University of Beirut | B.S. |
|---|---|---|
| Professional Medical | Medicine - American University of Beirut | M.D. |
| Residency | Internal Medicine - University of Iowa Hospitals & Clinics | Resident |
| Fellowship | Allergy and Immunology - University of Iowa Hospitals & Clinics | Fellow |
| Fellowship | Medical Oncology - University of Iowa Hospitals & Clinics | Fellow |
Selected Publications
Journal Article
- Han SS, Tompkins VS, Son DJ, Kamberos NL, Stunz LL, Halwani A, Bishop GA, Janz S (2013). Piperlongumine inhibits LMP1/MYC-dependent mouse B-lymphoma cells. Biochem Biophys Res Commun, 436(4), 660-5.
- Merryman RW, Kim HT, Zinzani PL, Carlo-Stella C, Ansell SM, Perales MA, Avigdor A, Halwani AS, Houot R, Marchand T, Dhedin N, Lescaut W, Thiebaut-Bertrand A, François S, Stamatoullas-Bastard A, Rohrlich PS, Labussière Wallet H, Castagna L, Santoro A, Bachanova V, Bresler SC, Srivastava A, Kim H, Pesek E, Chammas M, Reynolds C, Ho VT, Antin JH, Ritz J, Soiffer RJ, Armand (2017). Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood, 129(10), 1380-1388.
- Vrontikis A, Carey J, Gilreath JA, Halwani A, Stephens DM, Sweetenham J (2016). Proposed Algorithm for Managing Ibrutinib-Related Atrial Fibrillation. Oncology (Williston Park, N.Y.), 30(11), 970-4, 980-1, C3.
- Ontiveros EP, Halwani A, Stunz LL, Kamberos N, Olivier AK, Janz S, Bishop G (2014). A new model of LMP1-MYC interaction in B cell lymphoma. Leukemia & lymphoma, 55(12), 2917-23.
- Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ, Lebovic D, Dhodapkar M, Avigan D, Chapuy B, Ligon AH, Freeman GJ, Rodig SJ, Cattry D, Zhu L, Grosso JF, Bradley Garelik MB, Shipp MA, Borrello I, Timmerman (2016). Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. Journal of clinical oncology, 34(23), 2698-704.
- Colonna S, Halwani A, Ying J, Buys S, Sweeney (2015). Women with breast cancer in the Veterans Health Administration: demographics, breast cancer characteristics, and trends. Medical care, 53(4 Suppl 1), S149-55.
- Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand (2015). PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. The New England journal of medicine, 372(4), 311-9.
- McPherson JP, Vrontikis A, Sedillo C, Halwani AS, Gilreath J (2016). Pralatrexate Monitoring Using a Commercially Available Methotrexate Assay to Avoid Potential Drug Interactions. Pharmacotherapy, 36(2), e8-e11.
- Racila E, Link BK, Weng WK, Witzig TE, Ansell S, Maurer MJ, Huang J, Dahle C, Halwani A, Levy R, Weiner G (2008). A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clinical cancer research, 14(20), 6697-703.
- Elkeeb D, Hopkins Z, Miles RR, Halwani A, Wada (2018). Ominous cutaneous presentation of acute myeloid leukemia without peripheral blood involvement upon initial presentation and relapse: case report and literature review. European journal of dermatology, 28(6), 809-817.
- Burningham Z, Chen W, Sauer BC, Richter Lagha R, Hansen J, Huynh T, Patel S, Leng J, Halwani A, Kramer B (2019). VA Geriatric Scholars Program's impact on prescribing potentially inappropriate medications. The American journal of managed care, 25(9), 425-430.
- Halwani AS, Rasmussen KM, Patil V, Li CC, Yong CM, Burningham Z, Gupta S, Narayanan S, Lin SW, Carroll S, Mhatre SK, Graff JN, Dreicer R, Sauer B (2020). Real-world practice patterns in veterans with metastatic castration-resistant prostate cancer. Urologic oncology, 38(1), 1.e1-1.e10.
- Nelson SD, Lu CC, Teng CC, Leng J, Cannon GW, He T, Zeng Q, Halwani A, Sauer (2015). The use of natural language processing of infusion notes to identify outpatient infusions. Pharmacoepidemiology and drug safety, 24(1), 86-92.
- Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M, MAVORIC Investigators (2018). Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. The Lancet. Oncology, 19(9), 1192-1204.
- Halwani AS, Link B (2011). Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma. Expert review of anticancer therapy, 11(3), 443-55.
- Passey DG, Healy R, Qualls J, Halwani A, Sauer B (2020). Pharmacist-led collaborative medication management programs for oral antineoplastic therapies: A systematic literature review. Journal of the American Pharmacists Association, 61(3), e7-e18.
- Mehta-Shah N, Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Clemens MW, Dogan A, Fisher K, Goodman AM, Goyal G, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Lunning MA, Mehta A, Olsen EA, Pro B, Rajguru SA, Shanbhag S, Shaver A, Shustov A, Sokol L, Torka P, Torres-Cabala C, Wilcox R, William BM, Zain J, Dwyer MA, Sundar H, Kim Y (2020). NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020. Journal of the National Comprehensive Cancer Network, 18(5), 522-536.
- Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Clemens MW, Dogan A, Goodman AM, Goyal G, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kim YH, Mehta-Shah N, Olsen EA, Pro B, Rajguru SA, Rozati S, Said J, Shaver A, Shustov A, Sokol L, Torka P, Torres-Cabala C, Wilcox R, William BM, Zain J, Dwyer MA, Sundar (2020). NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021. Journal of the National Comprehensive Cancer Network, 18(11), 1460-1467.
- Horwitz SM, Ansell SM, Ai WZ, Barnes J, Barta SK, Choi M, Clemens MW, Dogan A, Greer JP, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Kim YH, Lunning MA, Mehta A, Mehta-Shah N, Oki Y, Olsen EA, Pro B, Rajguru SA, Shanbhag S, Shustov A, Sokol L, Torka P, Wilcox R, William B, Zain J, Dwyer MA, Sundar (2018). NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018. Journal of the National Comprehensive Cancer Network, 16(2), 123-135.
- Li C, Patil V, Rasmussen KM, Yong C, Chien HC, Morreall D, Humpherys J, Sauer BC, Burningham Z, Halwani A (2021). Predicting Survival in Veterans with Follicular Lymphoma Using Structured Electronic Health Record Information and Machine Learning. International journal of environmental research and public health, 18(5),
- Chien HC, Morreall D, Patil V, Rasmussen KM, Li C, Yong CM, Burningham Z, Masaquel A, Halloran M, De Long-Sieg E, Schulz M, Sauer BC, Halwani A (2021). Real-world practice patterns and outcomes in Veterans with relapsed/refractory diffuse large B-cell lymphoma. Future oncology (London, England), 17(4), 411-422.
- Chien HC, Morreall D, Patil V, Rasmussen KM, Yong C, Li C, Passey DG, Burningham Z, Sauer BC, Halwani A (2021). Treatment Patterns and Outcomes in a Nationwide Cohort of Older and Younger Veterans with Waldenström Macroglobulinemia, 2006-2019. Cancers, 13(7),
- Richter Lagha R, Burningham Z, Sauer BC, Leng J, Peters C, Huynh T, Patel S, Halwani AS, Kramer B (2020). Usability Testing a Potentially Inappropriate Medication Dashboard: A Core Component of the Dashboard Development Process. Applied clinical informatics, 11(4), 528-534.
- Rasmussen KM, Patil V, Burningham Z, Yong C, Sauer BC, Halwani A (2020). Atrial Fibrillation and Bleeding in Patients With Chronic Lymphocytic Leukemia Treated with Ibrutinib in the Veterans Health Administration. Federal practitioner, 37(Suppl 2), S44-S49.
- Halwani AS, Rasmussen KM, Patil V, Morreall D, Li C, Yong C, Burningham Z, Dawson K, Masaquel A, Henderson K, DeLong-Sieg E, Sauer B (2020). Maintenance rituximab in Veterans with follicular lymphoma. Cancer medicine, 9(20), 7537-7547.
- Burningham Z, Leng J, Peters CB, Huynh T, Halwani A, Rupper R, Hicken B, Sauer B (2018). Predicting Psychiatric Hospitalizations among Elderly Veterans with a History of Mental Health Disease. EGEMS (Washington, DC), 6(1), 7.
- Peters CB, Hansen JL, Halwani A, Cho ME, Leng J, Huynh T, Burningham Z, Caloyeras J, Matsuda T, Sauer B (2019). Validation of Algorithms Used to Identify Red Blood Cell Transfusion Related Admissions in Veteran Patients with End Stage Renal Disease. EGEMS (Washington, DC), 7(1), 23.
- Walsh JA, Pei S, Penmetsa GK, Sauer BC, Patil V, Walker JH, Clewell J, Douglas KM, Clegg DO, Cannon GW, Halwani (2019). Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis. Journal of managed care & specialty pharmacy, 25(11), 1218-1228.
- Burningham Z, Jackson GL, Kelleher JL, Morris I, Stevens MB, Cohen J, Maloney G, Sauer BC, Halwani AS, Chen W, Vaughan C (2023). Use of a Medication Safety Audit and Feedback Tool in the Emergency Department Is Affected by Prescribing Characteristics. Applied clinical informatics, 14(4), 684-692.
- Rasmussen KM, Patil V, Li C, Yong C, Appukkuttan S, Grossman JP, Jhaveri J, Halwani A (2023). Survival Outcomes by Race and Ethnicity in Veterans With Nonmetastatic Castration-Resistant Prostate Cancer. JAMA network open, 6(10), e2337272.
- Fu YV, Ramachandran GK, Halwani A, McInnes BT, Xia F, Lybarger K, Yetisgen M, Uzuner (2024). CACER: Clinical concept Annotations for Cancer Events and Relations. Journal of the American Medical Informatics Association, 31(11), 2583-2594.
- Shepherd-Banigan M, Zullig LL, Berkowitz TSZ, Cummin G, Goldstein KM, Kelley MJ, Chawla N, Weidenbacher HJ, Hazra A, Halwani AS, Patil V, Rasmussen KM, Pace R, Colonna S, Moss (2024). Improving Cancer Care for Women Seeking Services in the Veterans Health Administration Through the Breast and Gynecological Oncology System of Excellence. Military medicine,
- Monreal I, Chappell H, Kiss R, Friedman DR, Akesson J, Sae-Hau M, Szumita L, Halwani A, Weiss E (2024). Understanding the Barriers to Clinical Trial Referral and Enrollment Among Oncology Providers Within the Veterans Health Administration. Military medicine,
- Shah H, Jang H, Kim S, Halwani A (2023). A comprehensive SEER registry analysis of elderly patients with classical Hodgkin lymphoma based on treatment era and race. British journal of haematology, 200(5), 579-586.
- Parsons MW, Wada DA, Halwani AS, Tao R, Gaffney D (2022). Improved overall survival over time in advanced stage mycosis fungoides: a cross-sectional study. Leukemia & lymphoma, 63(10), 2428-2435.
- Burningham Z, Lagha RR, Duford-Hutchinson B, Callaway-Lane C, Sauer BC, Halwani AS, Bell J, Huynh T, Douglas JR, Kramer B (2022). Developing the VA Geriatric Scholars Programs' Clinical Dashboards Using the PDSA Framework for Quality Improvement. Applied clinical informatics, 13(4), 961-970.
- Friedman DR, Halwani AS, Kelley M (2022). Reply to B.L. King-Kallimanis et al. JCO clinical cancer informatics, 6, e2200075.
- Abbott J, Corean J, Laggis C, Halwani A, Toydemir R, Miles R, Florell S, Wada (2022). Histological Transformation and Clonal Relationship of Subcutaneous Marginal Zone B-Cell Lymphoma and Diffuse Large B-Cell Lymphoma. The American Journal of dermatopathology, 44(6), 442-448.
- Passey D, Healy R, Qualls J, Hamilton CJ, Tilley E, Burningham Z, Sauer B, Halwani (2022). Development and implementation of a pharmacist-led telehealth medication management program for veterans receiving oral antineoplastic therapies through the MISSION Act. American journal of health-system pharmacy, 79(11), 835-843.
- Halwani AS, Panizo C, Isufi I, Herrera AF, Okada CY, Cull EH, Kis B, Chaves JM, Bartlett NL, Ai W, de la Cruz-Merino L, Bryan LJ, Houot R, Linton K, Briones J, Chau I, von Keudell GR, Lu H, Yakovich A, Chen M, Meulen Jh T, Yurasov S, Hsu FJ, Flowers C (2022). Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. Leukemia & lymphoma, 63(4), 821-833.
- Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Brammer J, Clemens MW, Dogan A, Foss F, Ghione P, Goodman AM, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kallam A, Kim YH, Kumar K, Mehta-Shah N, Olsen EA, Rajguru SA, Rozati S, Said J, Shaver A, Shea L, Shinohara MM, Sokol L, Torres-Cabala C, Wilcox R, Wu P, Zain J, Dwyer M, Sundar (2022). T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 20(3), 285-308.
- Friedman DR, Patil V, Li C, Rassmussen KM, Burningham Z, Hamilton-Hill S, Kelley MJ, Halwani A (2022). Integration of Patient-Reported Outcome Measures in the Electronic Health Record: The Veterans Affairs Experience. JCO clinical cancer informatics, 6, e2100086.
- Shepherd-Banigan M, Cummin GL, Berkowitz TS, Weidenbacher HJ, Moss H, Chawla N, Goldstein KM, Hazra A, Bayley EM, Colonna S, Smith I, Halwani AS, Kelley MJ, Zullig L (2025). Prevalence of Toxic Exposures Among Women Veterans With Breast or Gynecologic Cancers Receiving Veterans Affairs (VA) Care. Military medicine,
- Li C, Stringer M, Patil V, Mcshinsky R, Morreall D, Yong C, Rasmussen KM, Burningham Z, Tamang S, Menendez CS, Chiba A, Moss HA, Colonna S, Rowe K, Friedman D, Kelley MJ, Halwani (2025). Using Open-Source Large Language Models to Identify Access to Germline Genetic Testing in Veterans With Breast Cancer From Unstructured Text. JCO clinical cancer informatics, 9, e2400263.
- Arabi S, Vardell V, Hanley T, Florell S, Halwani A, Lim (2025). Primary Cutaneous Gamma-Delta T-Cell Lymphoma Presenting With Hemophagocytic Lymphohistiocytosis in a Young Polynesian Male. Case reports in hematology, 2025, 8582804.
- Cui W, Halwani A, Li C, Finkelstein (2025). Predicting Prostate Cancer Diagnosis Using Machine Learning Analysis of Healthcare Utilization Patterns. Studies in health technology and informatics, 323, 6-10.
- Zullig LL, Shepherd-Banigan M, Cummin GL, Berkowitz TS, Melamed A, Weidenbacher H, Bayley EM, Colonna S, Hulen E, Patil V, Halwani A, Kelley MJ, Moss (2025). Characteristics of women Veterans with incident breast and gynecologic cancers in the Veterans Health Administration. Women's health (London, England), 21, 17455057251399013.
Review
- Post AR, Burningham Z, Halwani A (2022). Electronic Health Record Data in Cancer Learning Health Systems: Challenges and Opportunities. JCO clinical cancer informatics, 6, e2100158.
Letter
- Chien HC, Morreall D, Patil V, Rasmussen KM, Yong CM, Li CY, Passey DG, Burningham Z, Sauer BC, Halwani AS (2021). Real-world treatment patterns and outcomes in a national study of veterans with Waldenström macroglobulinemia, 2006-2019. [Letter to the editor]. Am J Hematol, 96(6), E184-E187.
- Laggis CW, Lamb A, Secrest AM, Ufkes N, Halwani AS, Tao R, Gaffney D, Miles RR, Florell SR, Wada (2021). Favourable outcomes in folliculotropic mycosis fungoides after multimodality treatment in a single institution. Journal of the European Academy of Dermatology and Venereology, 35(1), e42-e45.
Abstract
- Halwani A, Stunz S, Hu L, Janz S, Bishop (2010). A new mouse lymphoma model, the iMycEµ-LMP1 transgenic mouse, suggests collaboration of LMP1 and Myc in lymphomagenesis. Poster Presentation; University of Iowa Carver College of Medicine, College of Pharmacy, College of Public Health, Institute for Clinical and Translational Science and VA Health System Research Week.
- Halwani A, Ballas (2009). Progression of Selective IgM Deficiency to Common Variable Immunodeficiency. Journal of Allergy and Clinical Immunology. Poster Presentation, AAAAI annual meeting. 123(2, Supplement 1), S89.
- Halwani (2008). Eczematous Rash, Elevated IgE & Recurrent Infections. Presented at the Clinical Immunology Society Primary Immunodeficiency Summer School.
- Halwani A, Ballas (2008). Delayed Recovery of T Cell Response Post Cyclosporin Therapy. Journal of Allergy and Clinical Immunology. Poster Presentation, AAAAI annual meeting. 121(2, Supplement 1), S87.
- Halwani A, Gingrich (2005). An Unusual Tonsillitis. American College of Physicians, Iowa Chapter, Associates Clinical Vignette Competition.
- Kim YH, Bagot M, Eradat HA, Carson KR, Greer JP, Kim EJ, Kuzel T, Hughey LC, Poligone B, Lansigan F, Zinzani PL, Grandinetti LM, Procu P, Shustov AR, Korman NJ, Halwani A, Sokol L, Duvic M (2014). Phase 3 study of anti-CCR4 monoclonal antibody mogamulizumab vs vorinostat in relapsed or refractory cutaneous t-cell lymphoma (CTCL).
- Lesokhin A, Gutierrez M, Halwani A, Ansell SM, Armand P, Borrello I, Segota ZE, Cohen AD, Talpaz M, Cattry D, Turner T, Mezes M, Hartman C, Gupta A, Kim SY, Wigginton JM, Timmerman JM (2014). A Phase 1 Dose Escalation Study Evaluating the Effects of Nivolumab (anti-PD-1; BMS-936558) in Patients with Select Relapsed or Refractory Hematologic Malignancies.